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Recently, efforts to increase the toolkit which Escherichia coli cells possess for recombinant protein produc-
tion in industrial applications, has led to steady progress towards making glycosylated therapeutic pro-
teins. Although the desire to make therapeutically relevant complex proteins with elaborate human-
type glycans is amajor goal, the relatively poor efﬁciency of the N-glycosylation process of foreign proteins
in E. coli remains a hindrance for industry take-up. In this study, a systematic approach was used to
increase glycoprotein production titres of an exemplar protein, AcrA, and the resulting glycosylation efﬁ-
ciency was quantiﬁed using a combination of Western blots and pseudo Selective Reaction Monitoring
(pSRM). Western blot and pSRM results demonstrate that codon optimising the oligosaccharyltransferase,
PglB, for E. coli expression, increases efﬁciency by 77% and 101%, respectively. Furthermore, increasing
expression of glycosyltransferase, WecA, in E. coli improves efﬁciency by 43% and 27%, respectively. How-
ever, increasing the amount of donor lipid used in the glycosylation process did not impact on the glyco-
sylation efﬁciency in this system, with this speciﬁc protein.
 2012 Elsevier Inc. Open access under CC BY license.1. Introduction the glycosylation efﬁciency, i.e. the percentage of glycosylated tar-The ambition of using bacteria to make complex post-transla-
tionally modiﬁed human protein therapeutics remains a major
challenge for the bioprocessing community. The motivation is to
use production systems that are less costly than mammalian
expression systems with a higher level of ﬁnal product control,
i.e. little or no heterogeneity, is leading to exciting progress.
Although expression of large functional complex proteins in
Escherichia coli, present problems of their own, steady progress
has been made [1]. The production of smaller therapeutic fragment
proteins, working alone or intended for therapeutic fusion proteins,
such as antibody fragments, has been demonstrated as an attractive
alternative [2–4]. Advantages of small therapeutic proteins include
ﬂexibility in structure which increases binding possibilities and en-
hanced penetration of tissues [2]. A signiﬁcant advantage is the re-
duced costs of production in E. coli. The ability to perform bacterial
N-glycosylation of target proteins in E. coli has been demonstrated
using the well characterised N-glycosylation pathway from
Campylobacter jejuni [5–7]. Although performed in an exemplar
protein, AcrA, sourced from C. jejuni, the process has been shown
to be functional although very inefﬁcient [6,8,9]. In previous work,Y license. 
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right).get protein compared to total target protein, of AcrA was reported
to be just 13% [8]. It is thought that the occupancy rate of a protein
with a speciﬁc sugar structure could be dependent on factors such
as the site of the glycosylation consensus sequence and export
pathways, but there is not a general rule [10–12]. The Pgl pathway
is not native to E. coli and therefore metabolic constraints may also
play a signiﬁcant role in glycosylation efﬁciency. For this reason, an
iterative metabolic engineering strategy was developed to identify
bottlenecks and highlight potential targets to improve glycosyla-
tion efﬁciency [8]. A discovery-driven proteomics workﬂow, using
chemical tagging was employed with a mixture model on graphs
(MMG) approach [13] to suggest pathways that could be altered.
An increase in expression of isocitrate lyase in the glycoxylate shunt
resulted in an increase in glycosylation efﬁciency of AcrA by almost
3-fold to 48% [8].
Recently, Schwarz et al. [9] glycosylated AcrA and two human
antibody fragments F8 and CH2, using a system where the native
enzyme undecaprenyl-phosphate alpha-N-acetylglucosaminyl 1-
phosphate transferase (WecA) in E. coli was used to add the initial
sugar N-acetylglucosamine (GlcNAc), the same initial sugar found
in human N-glycoproteins. They reported glycosylation efﬁciencies
of 40% and 5% for the antibody fragments, respectively. The overall
titres of recombinant protein were very low (personal communica-
tion-Flavio Schwarz) and therefore improvements are required in
overall recombinant protein production as well as glycosylation
efﬁciency. The research presented here was carried out to address
the glycosylation efﬁciency issue.
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using systematic genetic changes to the E. coli host cell system. A
codon optimised oligosaccharyltransferase gene (pglB) was tested
and quantiﬁed using Western blots and pseudo Selected Reaction
Monitoring (pSRM) (see Pandhal et al. [8]). Western blots give an
actual glycosylation efﬁciency percentage whereas pSRM conﬁrms
this value by providing fold difference changes in glycoprotein nor-
malised by total protein. The effect of increasing WecA expression
was also tested, as this glycosyltransferase recognises GlcNAc and
attaches the sugar to asparagine residues [14]. Finally, the increase
in expression of BacA was also tested. In this system, glycosylation
involves the transfer of a heptasaccharide from an undecaprenyl-
pyrophosphate donor to the asparagine side chain of proteins. BacA
confers undecaprenyl pyrophosphate phosphatase activity [15],
which potentially results in increased availability of undecaprenyl
phosphate for glycoprotein synthesis. An increase in glycosylation
efﬁciency from increased BacA presence would indicate this as a
bottleneck in this system. The targets for engineering cells are
shown in Fig. 1.2. Materials and methods
All materials were purchased from Sigma–Aldrich (Dorset, U.K.)
unless otherwise stated.
2.1. DNA cloning, PCR, mutagenesis and vectors
The chloramphenicol resistant vectors pACYCpgl [7] and
pACYCpgl2 [9] were implemented here to perform the N-glycosyla-
tion process. PglB is present on both vectors, but was removed in
pACYCpgl to create pACYCpglDpglB. Brieﬂy, pACYCpglwas digested
with BaeI (NEB, Herfordshire, UK) at 37 C for 1 h. After conﬁrma-
tion by agarose gel electrophoresis, the linear DNA was digested
with exonuclease BAL-31 (NEB) for 5, 10, 20 and 30 min at 30 C.
The reaction was stopped by addition of SureClean reagent (Bioline,
London, UK). Overhangs were ﬁlled in using Phusion polymerase
(NEB) following the manufacturer’s instructions. After further
clean-up using SureClean reagent, vectors from all four time pointsFig. 1. A schematic representation of an E. coli cell harbouring N-glycosylation
capability. The systematic cellular engineering targets are shown as black boxes
with white borders. The order of steps involved in the N-glycosylation can be
followed using the black dashed arrows. Brieﬂy, a lipid linked oligosaccharide is
built in the cytoplasm using WecA to add the initial GlcNAc sugar to the
phosphorylated lipid. This is transferred using PglK ﬂippase to the periplasm,
where the oligosaccharyltransferase, PglB, recognises the structure and transfers it
onto the target protein (AcrA) on the appropriate consensus sequence. P = phos-
phate group.were re-ligated using T4 DNA ligase (NEB) with manufacturer’s
instructions for one hour at 37 C. Plasmids were transformed into
NEB5alpha competent cells (NEB) and a colony screen (forward pri-
mer GTGATAAAAATCCTATTCTC, reverse primer ACGCGATGCTTT
GAAATATT) was performed. Brieﬂy, sterile pipette tips were used
to transfer colonies into 5 lL water for subsequent PCR and also
to re-streak colonies on fresh LB agar (with antibiotics). The PCR
program was as follows: 95 C for 5 min, and 30 cycles of 95 C
for 30 s, annealing at 55 C for 30 s and extension at 72 C for times
depending on the expected insert size. A ﬁnal extension step of
72 C for 10 min was included. Following agarose gel electrophore-
sis, PCR products that visually looked reduced in size were sent for
sequencing at the Core Genome Facility (University of Shefﬁeld).
Plasmids with removed pglB were further tested phenotypically
using Western blots to see if glycosylation was abolished (Western
blot in Supplementary materials).
A codon optimised pglB gene was synthesised by DNA 2.0 (CA,
USA) using the GeneDesigner software algorithm. The codon opti-
mised sequence is given in the Supplementary materials, with
screenshots of how the software is used. The gene was provided
on vector pjexpress401 with kanamycin resistance and named
pjexpress401pglB⁄.
WecA was ampliﬁed from E. coli K12 DNA using the primer se-
quences presented in the Supplementary materials. PCR was per-
formed as described previously [8], but with an annealing
temperature of 57 C. The ampliﬁed gene was puriﬁed using Sure-
Clean reagent and digested with restriction enzymes BamHI and
XmaI for 1 h at 37 C. The same digestion was performed on vector
pjexpress401pglB⁄. The vector backbone was puriﬁed using a gel
extraction kit (Zymoresearch, Cambridge) and ligated to wecA
using T4 DNA ligase. The vector was named pjexpress401wecA.
This procedure was repeated using bacA ampliﬁed from E. coli
K12 DNA using primers given in the Supplementary materials.
However, BamHI and XbaI digestion was used prior to ligation. This
vector was named pjexpress401bacA. The native (non-codon opti-
mised) pglB gene was also ampliﬁed from the original pACYCpgl
vector and inserted into pjexpress401 to make pjexpress401pglB
using a similar procedure described above. This vector was used
to re-introduce pglB activity to cells to test pACYCpglDpglB muta-
tion and serve as a control of pjexpress401pglB⁄.
2.2. Cell growth, induction and harvesting
E. coli CLM24 cells [5] were used as host cells for this study.
Ampicilin, kanamycin and chloramphenicol concentrations of
50 lg/ml were used where appropriate. Overnight cultures were
used to seed 500 ml of LB-broth and grown at 37 C with shaking
at 180 rpm. When the optical density (O.D.) at 600 nm reached
0.5, cells were induced with 0.2% L-arabinose and 20 lM IPTG.
20 O.D. units worth of cells were harvested 3 h post induction via
centrifugation at 10,000g for 15 min at 4 C.
2.3. Protein puriﬁcation
Proteins from the periplasm were prepped and AcrA puriﬁed
using his-tag puriﬁcation as described previously [8]. The resulting
his-tag puriﬁcation was prepared for quantitation using pSRM and
Western blotting [8].
2.4. Western blots
Western blots were performed as described previously [8], ex-
cept for alterations described brieﬂy below. His-tag puriﬁed pro-
tein samples were quantiﬁed using RC/DC assay (BioRad, UK)
and 5 lg of total protein was loaded in each well (in 15 lL) com-
bined with 4 loading buffer (1 M Tris–HCl(pH 6.8), 20% glycerol,
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mercaptoethanol) and loaded onto SDS–PAGE gels. After transfer
to nitrocellulose membrane using an iBlot Dry Blotting System
(Life Technologies, CA, USA), membranes were probed using
0.5 lL anti-C-terminal his-tag antibody (Sigma see manufacturer’s
instructions). Detection was performed using chemiluminescence
with Immobilin horseradish peroxidase (HRP) substrate (Milli-
pore, Watford, UK). Western blots were visualised and quantiﬁed
using VisionWorks LS (Cambridge, UK). Glycosylation efﬁciency
was calculated as a percentage using intensity of glycoprotein over
intensity of total (glycosylated and aglycosylated) protein.
2.5. pseudo Selective Reaction Monitoring (pSRM)
Samples were prepared for MS analysis by in-gel trypsin diges-
tion as described previously [8]. After peptide extraction, the sam-
ples were dried and resuspended in buffer I (3% acetonitrile, 0.1%
formic acid) ready for targeted MS quantitation. Brieﬂy, an HCT
Ultra PTM discovery ESI-Ion Trap MS/MS (Bruker Daltonics, Coven-
try UK) was used to perform high selectivity pSRM measurements
of target peptides. The MS was operated in Ultrascan mode with a
3m/z window. Ion accumulation was set to 180,000 with accumu-
lation maximum of 200 ms. The intact masses and fragmentation
transitions were monitored with 3 microscan averages. Reverse
phase separation of peptides was achieved online using a micro-
ﬂow Ultimate 3000 LC system (Dionex, Surrey, U.K.) with 5% buffer
II (97% acetonitrile, 0.1% formic acids) for 10 min followed by an
increment to 40% buffer II for 30 min. A 90% buffer B for 10 min
was then followed by a ﬁnal return to 5% buffer B for 10 min.
The pSRM scans were analysed using DataAnalysis v4.0
(BrukerDaltonics, Coventry UK). The mean peak area ratios of the
three technical replicates runs for each sample was compared to
the control for each phenotype and relative values were recorded.
This was repeated for biological replicate samples. Changes in gly-
cosylation efﬁciency were calculated by normalising glycopeptide
relative changes to total protein changes (calculated from agly-
cosylated peptide intensities) and shown as a percentage.3. Results and discussion
The growth rates of engineered E. coli CLM24 cells were not
compromised signiﬁcantly compared to the control cells (see Sup-
plementary materials). The Western blot analysis had the advan-
tage of calculating an actual glycosylation efﬁciency value by
comparing glycosylated to aglycosylated band intensity. Although
pSRM was limited to revealing a fold change in glycosylation efﬁ-
ciency only, variation across biological replicates was lower using
pSRM compared to Western blot analysis (10% compared to 30%
respectively). The average technical variation using pSRM was
19%. Table 1 shows the pSRM peptide targets and elution times.
Example spectra are given in the Supplementary materials.
Codon optimised oligosaccharyltransferase PglB was compared
against standard PglB using pjexpress401 vectors and
pACYCpglDpglB, where the native pglB gene had been deleted. Cells
were induced to express both versions of oligosaccharyltransferase
as well as the target glycoprotein AcrA. In order to conﬁrm theTable 1
pSRM targets. The following peptide m/z values were programmed into the HCT Ultra MR
Peptide Modiﬁcation* Precursor m
NGFKVPQIGVK N/A 1185.7
LYFIDSVIDANSGTVK N/A 1742.0
AVFDNN*NSTLLPGAFATITSEGFIQK Bac(GalNAc)5Glc 4161.1
ATFENASKDFN*R GlcNAc(GalNAc)5 2779.5
* Bac: bacillosamine, GalNAc: N-acetylgalactosamine, GlcNAc: N-acetylglucosamine, Glcdeletion of the pglB gene from pACYCpgl, E. coli CLM24 cells were
induced to produce AcrA with the vectors pECacrA and
pACYCpglDpglB. Western blot analysis showed the presence of
one band, and therefore indicated that only aglycosylated AcrA
was present (see Supplementary materials). This conﬁrmed the
deletion, as PglB is not present to transfer the glycan onto the pro-
tein and hence no glycoprotein is detected. These cells were further
transformed with either (i) vector pjexpress401pglB or (ii) vector
pjexpress401pglB⁄. The resulting Western blot analysis shows
multiple bands indicative of modiﬁed AcrA protein (mono and
di-glycosylated) (see Supplementary materials).
Fig. 2A–C shows Western blot and pSRM quantiﬁcations of AcrA
from E. coli CLM24 cells containing pACYCpglDpglB and supple-
mented with (i) pjexpress401pglB and (ii) pjexpress401pglB⁄.
Quantiﬁcations of theWestern blot show an overall increase in gly-
cosylation efﬁciency of 77 ± 27% in cells with codon optimised pglB
compared to non-codon optimised pglB. pSRM results show a
101 ± 26% increase in efﬁciency when pglB is codon optimised.
These results imply that improved expression levels of pglB in
the glycosylation pathway could be a bottleneck in the production
of glycosylated AcrA in E. coli cells and an increase in glycosylation
efﬁciency is evident by both Western blot and pSRM.
The BacA enzyme, native to E. coli, harbours undecaprenyl pyro-
phosphate phosphatase activity through conversion of undecapre-
nyl pyrophosphate (UND-PP) to undecaprenyl phosphate (UND-P)
[15]. This product is a key lipid intermediate involved in the syn-
thesis of cell wall polymers such as peptidoglycan. The UND-P lipid
is also required as a donor to add the attached heptasaccharide
sugar (donated from sugar nucleotide donors) to the glycosylation
consensus sequence on AcrA (D/E-Z-N-X-S/T, where X and Z can be
any amino acid except for proline). Therefore, an increase in BacA
would potentially increase the donor availability and increase gly-
cosylation efﬁciency. Fig. 2D–F shows quantiﬁcations of the Wes-
tern blot image and pSRM of E. coli CLM24 cells with pECacrA,
pACYCpgl and either a pjexpress401 control plasmid or pjex-
press401bacA. Quantiﬁcations using both methods show no signif-
icant change in glycosylation efﬁciency. It is therefore presumed
that undecaprenyl phosphate availability is not a glycosylation
limiting component in the E. coli system.
WecA protein is native to E. coli and involved in the initiation of
lipopolysaccharide synthesis [16]. This sugar transferase catalyses
the transfer of GlcNAc-1-phosphate onto undecaprenyl phosphate
(UND-P) to form UND-PP-GlcNAc. This protein can also transfer the
GlcNAc onto the UND-P as the initial sugar of the Campylobacter
heptasaccharide rather than the rare sugar bacillosamine. This
new sugar structure is recognised by PglK and PglB in the glycosyl-
ation process [5,17]. Mass spectral evidence of the different glycan
structure has been reported previously [7], although the abun-
dance difference of the two different types has not. Subsequently,
a pACYCpgl2 vector has been created in which the pgl pathway
was modiﬁed by deletion of pglD, pglE, pglC, pglF and pglI [9]. The
new glycan is a hexasaccharide of GlcNAc (GalNAc)6 (glucose is
also not added). In order to improve AcrA glycoprotein expression,
WecA synthesis was induced using the pjexpress401wecA vector
and the amount of glycoprotein with the new hexasaccharide
structure was quantiﬁed and compared to control cells. TheM software system.
ass m/z Transition ions Retention time (min)
396.2 416, 641 28.6
871.5 791, 904 36.4
1041.4 1696, 1798 39.9
927.7 1188, 1289 23.6
: glucose.
Fig. 2. (A–C) A comparison of glycosylation efﬁciency in cells expressing native pglB from C. jejuni (control) and codon optimised PglB (PglB⁄). (A) Western blot image. (B)
Glycosylation efﬁciency calculated fromWestern blot images in part A. (C) Log10 fold change in glycosylation efﬁciency calculated by Western blots in part A and pSRM. (D–
F) A comparison of glycosylation efﬁciency in cells over expressing bacA to control cells. (D) Western blot image. (B) Glycosylation efﬁciency calculated from Western blot
images in part D. (E) Log10 fold change in glycosylation efﬁciency calculated by Western blots in part D and pSRM. (G–I) A comparison of glycosylation efﬁciency in cells over
expressing wecA to control cells (G) Western blot image. (H) Glycosylation efﬁciency calculated from Western blot images in part G. (C) Log10 fold change in glycosylation
efﬁciency calculated by Western blots in part G and pSRM. The puriﬁed AcrA protein was probed with anti-C-terminal histidine antibody.
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43 ± 11% increase in glycosylation efﬁciency. pSRM calculations
show a 27 ± 5% in glycosylation efﬁciency. This increase, although
small, shows that WecA is a potential bottleneck for glycoprotein
production in the E. coli system. Increasing its expression level fur-
ther through IPTG induction, without comprising growth rate and
AcrA production, could improve this further.
The aim of using E. coli cells to economically produce therapeu-
tically relevant, glycosylated human protein therapeutics, requires
generating a strain which harbours the highest efﬁciency of post-
translationally modiﬁed target proteins. Metabolic engineering of
cells to improve the amount of protein which carry the speciﬁc gly-
cans is one approach, and progress has been made in this area by
identifying targets using proteomics and metabolic network anal-
ysis. This study involved targeting speciﬁc metabolic enzymes
and quantifying glycosylation efﬁciency using Western blots and
pSRM.
The percentage of glycosylated recombinant AcrA protein, pro-
duced in E. coli, was increased by improving expression levels of
oligosaccharyltransferase, pglB. The expression level was improved
by codon optimisation and translated to a 77%and 101% increase in
glycosylation efﬁciency (using Western blots and pSRM, respec-
tively). The hypothesis that lipid linked precursor could also be a
bottleneck was tested by increasing expression of bacA, which
has undecaprenyl pyrophosphate phosphatase activity. However,
Western blot analysis and pSRM quantiﬁcation provided evidence
that the hypothesis was unfounded with AcrA protein. The use of
the E. coli native enzyme WecA to add the same glycan as present
in human proteins, GlcNAc, was improved by increasing its expres-
sion. The modest increase in efﬁciency however (43% and 27%), im-
plies that E. coli cells would have to be modiﬁed in tandem with
other cellular engineering strategies in order to produce an ideal
host for human therapeutic protein production.
Acknowledgments
The authors acknowledge funding from the UK’s Biotechnology
and Biological Sciences Research Council (BBSRC) through the Bio-process Research Industry Club (BRIC) programme [BBF0048421]
and Research Experience Placements (REP) scheme. The authors
also acknowledge the Engineering and Physical Sciences Research
Council (EPSRC) [EP/E036252/1]. We would like to thank Chris
Noble, Valentina Igenegbai and Kristina Umbach (University of
Shefﬁeld) for technique optimisation help and Marcus Aebi (Swiss
Federal Institute of Technology (ETH), Zürich) for provision of Pgl2
plasmid.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbrc.2012.02.020.
References
[1] F. Baneyx, Recombinant protein expression in Escherichia coli, Curr. Opin.
Biotechnol. 10 (1999) 411–421.
[2] J.M. Liddell, Production strategies for antibody fragment therapeutics,
Biopharm Int. Suppl. (2009).
[3] M. Better, C.P. Chang, R.R. Robinson, A.H. Horwitz, Escherichia coli secretion of
an active chimeric antibody fragment, Science 240 (1988) 1041–1043.
[4] A. Skerra, A. Pluckthun, Assembly of a functional immunoglobulin Fv fragment
in Escherichia coli, Science 240 (1988) 1038–1041.
[5] M.F. Feldman, M. Wacker, M. Hernandez, P.G. Hitchen, C.L. Marolda, M.
Kowarik, H.R. Morris, A. Dell, M.A. Valvano, M. Aebi, Engineering N-linked
protein glycosylation with diverse O antigen lipopolysaccharide structures in
Escherichia coli, Proc. Natl. Acad. Sci. USA 102 (2005) 3016–3021.
[6] J. Pandhal, P.C. Wright, N-Linked glycoengineering for human therapeutic
proteins in bacteria, Biotechnol. Lett. 32 (2010) 1189–1198.
[7] M. Wacker, D. Linton, P.G. Hitchen, M. Nita-Lazar, S.M. Haslam, S.J. North, M.
Panico, H.R. Morris, A. Dell, B.W. Wren, M. Aebi, N-linked glycosylation in
Campylobacter jejuni and its functional transfer into E. coli, Science 298 (2002)
1790–1793.
[8] J. Pandhal, J. Noirel, S. Ow, P.C. Wright, Improving N-glycosylation efﬁciency in
Escherichia coli using shotgun proteomics, metabolic network analysis and
selective reaction monitoring, Biotechnol. Bioeng. 108 (2011) 902–912.
[9] F. Schwarz, W. Huang, C. Li, B. Schulz, C. Lizak, A. Palumbo, S. Numao, D. Neri,
M. Aebi, L. Wang, A combined method for producing homogeneous
glycoproteins with eukaryotic N-glycosylation, Nat. Chem. Biol. 6 (2010)
264–266.
[10] I. Nilsson, G. von Heijne, Glycosylation efﬁciency of Asn-Xaa-Thr sequons
depends both on the distance from the C terminus and on the presence of a
downstream transmembrane segment, J. Biol. Chem. 275 (2000) 17338–
17343.
476 J. Pandhal et al. / Biochemical and Biophysical Research Communications 419 (2012) 472–476[11] A.R. Walmsley, N.M. Hooper, Glycosylation efﬁciency of Asn-Xaa-Thr sequons
is independent of distance from the C-terminus in membrane dipeptidase,
Glycobiology 13 (2003) 641–646.
[12] A.C. Fisher, C.H. Haitjema, C. Guarino, E. Celik, C.E. Endicott, C.A. Reading, J.H.
Merritt, A.C. Ptak, S. Zhang, M.P. DeLisa, Production of secretory and
extracellular N-linked glycoproteins in Escherichia coli, Appl. Environ.
Microbiol. 77 (2011) 871–881.
[13] J. Noirel, G. Sanguinetti, P.C. Wright, Identifying differentially expressed
subnetworks with MMG, Bioinformatics 24 (2008) 2792–2793.
[14] A.O. Amer, M.A. Valvano, Conserved amino acid residues found in a predicted
cytosolic domain of the lipopolysaccharide biosynthetic protein WecA are
implicated in the recognition of UDP-N-acetylglucosamine, Microbiology 147
(2001) 3015–3025.[15] M. El Ghachi, A. Bouhss, D. Blanot, D. Mengin-Lecreulx, The bacA gene of
Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity,
J. Biol. Chem. 279 (2004) 30106–30113.
[16] J. Lehrer, K.A. Vigeant, L.D. Tatar, M.A. Valvano, Functional characterization and
membrane topology of Escherichia coli WecA, a sugar-phosphate transferase
initiating the biosynthesis of enterobacterial common antigen and O-antigen
lipopolysaccharide, J. Bacteriol. 189 (2007) 2618–2628.
[17] M. Wacker, M.F. Feldman, N. Callewaert, M. Kowarik, B.R. Clarke, N.L. Pohl, M.
Hernandez, E.D. Vines, M.A. Valvano, C. Whitﬁeld, M. Aebi, Substrate
speciﬁcity of bacterial oligosaccharyltransferase suggests a common transfer
mechanism for the bacterial and eukaryotic systems, Proc. Natl. Acad. Sci. USA
103 (2006) 7088–7093.
